Journal
JOURNAL OF NEUROLOGY
Volume 261, Issue 4, Pages 651-654Publisher
SPRINGER HEIDELBERG
DOI: 10.1007/s00415-013-7032-x
Keywords
Glioblastoma; Oligodendroglioma; Bevacizumab; Temozolomide; PCV
Categories
Ask authors/readers for more resources
The management of high-grade glioma (HGG) has evolved significantly over the last decade. Patients are managed in a multidisciplinary team setting in order to ensure their care is guided by the most current evidenced based treatments. The outcome in patients with HGG, while still poor, has improved in terms of both survival and quality of life during illness. This review discusses a number of developments seen in the management of HGG over the last 5 years.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
